Marshall R. Posner, MD, The Tisch Cancer Institute, New York, NY, describes an analysis of patients with locally advanced human papillomavirus (HPV)-positive oropharynx cancer (OPC) from two different trials (NCT02945631, NCT01706939) who received induction chemotherapy followed by de-escalated chemoradiotherapy. 32 patients, who had risk factors such as extranodal extensions, T4 lesions, or N2c disease were enrolled for analysis and had a favorable overall response (OS) and progression-free survival (PFS), with no treatment-related mortalities. The results highlight the efficacy of radiotherapy de-escalation for patients with locally advanced HPV positive OPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Marshall R. Posner, MD has received consultancy feed from Merck (DMC), Kura (ad board), Hookipa (ad board), BioNtech (ad board), and Naveris (ad board).